Jazz Pharmaceuticals Shares Rise Following Upward Revenue Guidance Revision
Jazz Pharmaceuticals (JAZZ) saw its stock price increase by approximately 8% during Tuesday morning trading following the release of third-quarter financial results. The company reported top-line revenue that exceeded market expectations, driving investor optimism. In addition to the quarterly beat, Jazz Pharmaceuticals raised its full-year revenue guidance for 2026. The updated forecast now places annual revenue between $4.775 billion and $4.85 billion, an increase from the previous projection of $4.6 billion to $4.75 billion. This upward revision aligns closely with the current market consensus of $4.8 billion.
Tickers: $JAZZ
Topics: earnings report revenue forecast stock price movement